A Phase 2 Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2017
At a glance
- Drugs Dalotuzumab (Primary) ; Ridaforolimus (Primary) ; Exemestane
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 18 Aug 2017 Planned End Date changed from 30 Jun 2017 to 31 Dec 2017.
- 31 Aug 2016 This study has been completed in Czech Republic as per European Clinical Trials database record.
- 21 Jul 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.